NeuroOne Medical Technologies (NASDAQ:NMTC) Announces Earnings Results, Beats Expectations By $0.29 EPS

NeuroOne Medical Technologies (NASDAQ:NMTC) posted its earnings results on Thursday. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.29, FiscalAI reports. NeuroOne Medical Technologies had a negative net margin of 71.50% and a negative return on equity of 115.61%. The business had revenue of $1.97 million for the quarter, compared to analysts’ expectations of $2.55 million.

Here are the key takeaways from NeuroOne Medical Technologies’ conference call:

• Third-quarter product revenue rose 16% year over year to $2.0 million, while product orders increased 43% to $2.7 million. Gross margin also expanded to 59.9% from 53.9%, driven by a favorable product mix.
• Manufacturing constraints left a $1.7 million backlog and caused management to lower expected fiscal 2026 recognized revenue to $9.2 million-$10.5 million, despite approximately $11.2 million in expected orders. A second, larger manufacturing site is targeted for early 2027.
• NeuroOne received ISO 13485 certification, enabling international commercialization of its OneRF Brain Ablation, OneRF Trigeminal Nerve Ablation, and Evo diagnostic product lines. The company plans to work with Zimmer Biomet and independent distributors to enter selected markets.
• The company reported progress across its pipeline, including clinical support for OneRF in patients with existing neuromodulation implants, expansion of trigeminal nerve ablation distribution, and preclinical collaborations for the StereoCED drug-delivery platform. StereoCED is expected to be ready for investigational human studies by the end of September, while the BVNA back-pain system is targeted for a 510(k) submission in the second half of calendar 2027.
• Cash and equivalents declined to $2.0 million as of June 30 from $6.6 million at fiscal year-end, while the quarterly net loss widened to $2.0 million from $1.5 million. The company raised $0.4 million during the quarter and another $1.0 million after quarter-end through its ATM program, indicating continued reliance on equity financing.

NeuroOne Medical Technologies Price Performance

NMTC stock traded up $0.11 during midday trading on Friday, reaching $1.94. The company had a trading volume of 94,081 shares, compared to its average volume of 66,326. The firm has a 50-day moving average price of $2.54 and a 200-day moving average price of $3.79. The company has a market capitalization of $16.88 million, a P/E ratio of -2.04 and a beta of 0.61. NeuroOne Medical Technologies has a 1 year low of $1.42 and a 1 year high of $6.96.

Insider Buying and Selling at NeuroOne Medical Technologies

In other news, Director Mark Christianson sold 10,000 shares of the firm’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $3.18, for a total transaction of $31,800.00. Following the sale, the director owned 20,692 shares in the company, valued at approximately $65,800.56. This trade represents a 32.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 11.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd increased its stake in NeuroOne Medical Technologies by 321.1% in the fourth quarter. XTX Topco Ltd now owns 85,454 shares of the company’s stock valued at $65,000 after acquiring an additional 65,163 shares during the last quarter. Squarepoint Ops LLC bought a new stake in NeuroOne Medical Technologies during the fourth quarter worth about $36,000. Essex Investment Management Co. LLC bought a new stake in NeuroOne Medical Technologies during the fourth quarter worth about $143,000. Renaissance Technologies LLC boosted its holdings in shares of NeuroOne Medical Technologies by 10.2% in the 4th quarter. Renaissance Technologies LLC now owns 763,028 shares of the company’s stock worth $578,000 after purchasing an additional 70,428 shares in the last quarter. Finally, Susquehanna International Group LLP purchased a new position in shares of NeuroOne Medical Technologies in the 3rd quarter worth about $47,000. Institutional investors own 16.07% of the company’s stock.

Wall Street Analyst Weigh In

NMTC has been the topic of several research analyst reports. Weiss Ratings raised shares of NeuroOne Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 28th. LADENBURG THALM/SH SH lifted their price objective on NeuroOne Medical Technologies from $1.60 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, May 13th. Finally, Maxim Group set a $5.00 target price on NeuroOne Medical Technologies and gave the stock a “buy” rating in a research report on Friday. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $7.33.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.